Introduction

Mastocytosis is an uncommMSc in Precision Medicine and Pharmacological Innovation, University of Glasgowon problem that is described as an unusual build-up and trigger of mast cells in the skin, bone marrow, and inside organs (liver, spleen, gastrointestinal tract, and lymph nodes). Both youngsters and adults can be impacted by mastocytosis.¹ 

Two primary forms of mastocytosis exist:

• Cutaneous mastocytosis, which primarily affects young people, where mast cells in the skin, yet are not found in huge numbers somewhere else in the body
• Systemic mastocytosis, which predominantly influences adults, is characterized by the accumulation of mast cells in bodily tissues, like the skin, internal organs, and bones²

Pathophysiology of mastocytosis

The pathogenesis of a wide range of mastocytosis is the consequence of the ongoing and intermittent release of mast cell mediators and increased build-up of mast cells in one or more tissues. Various vasoactive mediators are present in mast cells, which typically release these chemicals to create inflammatory responses to defend the body from pathogens and stressors. The symptoms and adverse reactions linked to the sudden and extensive secretion of mast cell mediators are similar to allergic and anaphylactic responses. One gene called KIT, which codes for CD117 transmembrane tyrosine kinase, regulates mast cell secretion. Mast cell movement, survival, and proliferation are all aided by CD117. Kit mutations are primarily somatic; they may be present from birth but do not appear inherited.³

Several transformations can activate the c-kit oncogene receptor without needing its ligand. Two areas of c-kit include mutations linked to mastocytosis: exon 11 and, all the more critically, exon 17. These changes lead to clonal growth through ligand-free constitutional activation. These changes have been observed in over 90% of mastocytosis cases. In a nutshell, it seems that activating c-kit mutations are required to develop mastocytosis, while phenotypic variety could be connected with the blend of these changes with other mutations or acquired hereditary polymorphisms.⁴

Signs & symptoms

The signs and symptoms of systemic mastocytosis are determined by the body part affected by an excess of mast cells. The side effects of mastocytosis are principally caused by chemicals being released from the mast cells, leading to allergic reaction-like symptoms. However, it may be difficult to identify a specific allergic trigger. Common side effects include flushing and increased gastric acid production due to histamine release from mast cells. Skin lesions are the hallmark of cutaneous mastocytosis. These lesions typically appear on the trunk and limbs instead of the head and neck. There could be diarrhea, bloating, stomach aches, discomfort in the abdomen, and indigestion. There is a possibility of liver, spleen, and lymph node enlargement in the advanced stage of the disease.^{1, 2}

Inflammatory and symptom-causing chemicals are released by the activated mast cells. While each person has unique triggers, the following are the most typical ones:

• Insect sting
• Physical and emotional stress
• Alcohol
• Spicy foods
• Medications⁵

Psychological impact of mastocytosis

Psychological symptoms seem to be a common experience among patients with mastocytosis, which might have a major negative impact on their quality of life. However, it is still unclear how much of this is true. Apart from psychological symptoms, the physical side effects that are related to mastocytosis likewise essentially affect the quality of life of patients with this condition. In addition to these clinical side effects, prior examinations have reliably tracked down the higher incidence of psychiatric issues in mastocytosis patients. This result may be attributed to the impact of different mast cell mediators on brain activity. It is still unknown whether psychological problems are specifically linked to mastocytosis or if they are the general result of coping with a chronic, physically incapacitating illness. To comprehend the nature and severity of mental side effects in patients with mastocytosis, it seems helpful to make examinations of emotional and physical distress levels in patients with different diseases.⁶

Anxiety and depression

It is known that mast cells exist in the brain, affecting emotional, cognitive, and behavioral functions, leading to symptoms such as anxiety and depression, as well as conditions including autism and neurological illnesses. It is likewise revealed that high levels of depression and cognitive impairment occur in Mastocytosis patients. Indeed, it is conceivable that chemicals secreted by mast cells in the brain are engaged with some level of a neuropsychological alteration affecting the patient's life, functioning, and overall wellness. Like other challenging medical conditions, mast cell illnesses may contribute to emotional, cognitive, and behavioral difficulties or alterations.⁷ 

It has been determined that depression in mastocytosis may be connected with mast cell activation. Masitinib may be a beneficial treatment for mastocytosis patients experiencing anxiety and depressive symptoms. Its inhibitory effect leads to cell cycle arrest and apoptosis of cell lines dependent on KIT signaling. This can help reduce mast cell issues and tryptase levels, which may have a positive impact on depression through a related process.

Patients with mastocytosis present numerous psychopathological indications. These appearances are primarily portrayed by mental weakness (low ability to focus, trouble concentrating, and distraction) and negative emotionality (depression, low motivation, vulnerability to stress, and nervousness).

Brain mast cells have been demonstrated to trigger hypothalamic-pituitary-adrenal reactions through secreting histamine and corticotropin-delivering factors centrally. Additionally, the overproduction of cortisol and the malfunction of the hypothalamic-pituitary-adrenal hub appear to play a role in the medical complications linked with mood disorders. The findings highlight the fact that, by selectively targeting MC, masitinib seems to have a positive effect on anxiety and depression symptoms in addition to the physical symptoms of mastocytosis.⁸

Stress and coping mechanism

Psychological stress deteriorates atopic illnesses, particularly asthma, atopic dermatitis, and mastocytosis. It is the most widely recognized trigger of mastocytosis and mast cell (MC) activation syndrome, which are portrayed by an expanded number of MCs or their reactivity.

Stress causes the hypothalamus to release corticotropin-releasing hormone (CRH), which activates the HPA axis and is generally related to anti-inflammatory effects. Elevated levels of CRH have been linked to psychological stress in patients with systemic or cutaneous mastocytosis, psoriasis, and atopic dermatitis.⁹

Individuals who use adaptive coping strategies for dealing with mast cell disorders, like planning and looking for social help, tend to experience lower levels of anxiety. In contrast, individuals who resort to avoidant survival techniques might encounter more elevated levels of stress. Problem-focused coping involves directly addressing stressors by creating a plan of action and focusing on solutions. It is recommended that interventions aimed at coping skills may be able to lessen emotional discomfort in patients suffering from mast cell diseases. Providing support for effective coping is therefore a crucial goal, considering the lack of established treatments for this debilitating disorder.¹⁰

Diagnosis

In cutaneous mastocytosis, a diagnosis can be confirmed on the look of the skin and a skin biopsy can reveal a large number of mast cells. To confirm the diagnosis of systemic mastocytosis, a bone marrow biopsy should be performed, which would demonstrate an unusually high number of mast cells with a strange appearance.¹

Healthcare providers might also request the following tests:

• Blood test to measure the level of tryptase
• Bone scans to examine for indications of bone deterioration
• Genetic tests to look for mutated KIT genes in systemic mastocytosis.¹¹

Treatment

The symptoms and the type of mastocytosis determine the plan of treatment. Generally speaking, medical professionals employ drugs and other therapies to reduce symptoms.  Treatment shifts in light of mastocytosis type and your side effects. As a general rule, professionals use prescriptions and different medicines to ease side effects.

Prescriptions for mastocytosis may include:

• H2 blockers (Antacids) for digestive problems.
• Antihistamines: to ease skin allergies such as flushing and itching
• Bisphosphonates for osteoporosis.
• Corticosteroids, to lessen inflammation.
• Medication for pain.

Professionals might utilize the following therapies:

• Bright (UV) light, to make obscured skin injuries less observable.
• Targeted therapy treatment.
• Anaphylaxis is treated with epinephrine.
• Chemotherapy, in case cancer develops from mastocytosis. 
• Allogeneic stem cell (bone marrow) transplantation to treat progressive or aggressive mastocytosis. This treatment may not be beneficial for very many mastocytosis patients.¹¹

FAQs

How common is mastocytosis?

Worldwide, it is estimated that one in 10,000 to 20,000 people will develop mastocytosis. Any age can be affected by the illness, including adulthood. Men and women are equally affected.

Is mastocytosis cancerous?

Systemic aggressive mastocytosis rarely progresses into mast cell leukemia. A malignancy called mast cell leukemia develops in the bone marrow and blood. 

Are there any side effects of mastocytosis treatments? 

Mastocytosis symptoms can be treated with a variety of methods. The majority of treatments come with side effects, some more serious than others. Healthcare professionals will tell you what to expect, including any side effects from the treatment, if you have mastocytosis.

Summary

Mastocytosis significantly affects the physical and mental well-being of affected individuals due to its complicated pathophysiology and diverse symptoms. The disorder can manifest in diverse ways across different age groups, as demonstrated by the distinction between its cutaneous and systemic forms. Comprehensive approaches to diagnosis and treatment are required due to the chronic nature of mastocytosis, characterized by genetic mutations and the persistent release of mediators from mast cells. For comprehensive patient care, it is essential to address the psychological effects, such as anxiety and depression. A combination of medications to control physical symptoms and coping mechanisms-enhancing support systems is required for effective management. To improve mastocytosis patients' diagnosis, treatment options, and overall quality of life, ongoing research and awareness are essential.